Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

BUY
$132.34 - $159.14 $542,594 - $652,474
4,100 New
4,100 $652,000
Q2 2022

Aug 12, 2022

BUY
$103.24 - $121.81 $2.43 Million - $2.87 Million
23,531 Added 35.52%
89,776 $10 Million
Q1 2022

May 13, 2022

SELL
$93.1 - $112.54 $72,431 - $87,556
-778 Reduced 1.16%
66,245 $7.36 Million
Q4 2021

Feb 11, 2022

SELL
$95.88 - $117.08 $893,505 - $1.09 Million
-9,319 Reduced 12.21%
67,023 $7.51 Million
Q3 2021

Nov 10, 2021

BUY
$84.42 - $106.62 $4.8 Million - $6.07 Million
56,897 Added 292.6%
76,342 $7.33 Million
Q2 2021

Aug 16, 2021

SELL
$67.66 - $84.76 $118,540 - $148,499
-1,752 Reduced 8.27%
19,445 $1.63 Million
Q1 2021

May 13, 2021

BUY
$67.06 - $75.82 $78,728 - $89,012
1,174 Added 5.86%
21,197 $1.43 Million
Q4 2020

Feb 16, 2021

BUY
$63.89 - $73.8 $266,101 - $307,377
4,165 Added 26.26%
20,023 $1.4 Million
Q3 2020

Nov 13, 2020

BUY
$63.69 - $70.22 $23,628 - $26,051
371 Added 2.4%
15,858 $1.1 Million
Q2 2020

Aug 14, 2020

BUY
$58.54 - $67.94 $341,463 - $396,294
5,833 Added 60.42%
15,487 $1.01 Million
Q1 2020

May 14, 2020

BUY
$49.46 - $64.78 $85,120 - $111,486
1,721 Added 21.69%
9,654 $581,000
Q4 2019

Feb 13, 2020

BUY
$49.86 - $58.26 $71,100 - $83,078
1,426 Added 21.91%
7,933 $459,000
Q3 2019

Nov 13, 2019

BUY
$47.54 - $53.43 $23,770 - $26,715
500 Added 8.32%
6,507 $336,000
Q2 2019

Aug 08, 2019

BUY
$46.79 - $52.47 $20,681 - $23,191
442 Added 7.94%
6,007 $306,000
Q1 2019

May 13, 2019

BUY
$46.36 - $52.63 $34,074 - $38,683
735 Added 15.22%
5,565 $291,000
Q4 2018

Feb 14, 2019

BUY
$41.54 - $47.25 $200,638 - $228,217
4,830 New
4,830 $223,000
Q1 2018

May 14, 2018

SELL
$48.49 - $58.14 $187,510 - $224,827
-3,867 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$47.53 - $53.73 $183,798 - $207,773
3,867
3,867 $208,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $246B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.